Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
July 24, 2006

“Therapeutic Intent” in Phase 1 Oncology TrialsA Justifiable Objective

Author Affiliations

Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006

Arch Intern Med. 2006;166(14):1446-1448. doi:10.1001/archinte.166.14.1446

Much has been written over the past decade regarding the ethics of phase 1 studies in patients with malignant disease.18 A primary focus of this literature has been on the expressed concern that patients, and often their physicians, “misinterpret” the fundamental aims of such studies, believing either consciously, or unconsciously, that participation will be of direct clinical benefit to the research subject. Rather, the argument goes, the purpose of phase 1 trials is to “determine the metabolism and pharmacologic actions of the drug in humans, the adverse effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness,”9 information that will hopefully be of benefit to future patients.

First Page Preview View Large
First page PDF preview
First page PDF preview